Global commercial rights signed by ConvaTec Ltd for ChloraSolv, innovative wound debrider from RLS

21 June 2021

ConvaTec will be launching in Europe Chlorasolv, a gentle wound debrider efficient against biofilm, within the recognized Wound HygieneTM protocol of care, designed to accelerate healing in hard-to-heal wounds. 

ConvaTec, one of the world’s leading companies in advanced wound care and RLS Global, a medical healthcare company based in Sweden, have entered a global collaboration to commercialize ChloraSolv. ChloraSolv is a ground-breaking gentle debrider, which is already currently sold in some European countries. ChloraSolv will be included in ConvaTec’s Wound Hygiene
TM Protocol of care for hard-to-heal wounds, which was developed by Key Opinion Leaders (“KOLs”) and promoted by ConvaTec, where it will add a significant benefit in terms of debridement solutions.

The collaboration includes rights to commercialize ChloraSolv in Europe with immediate effect, and future rights to commercialize in the USA and Rest of World (“ROW”) upon regulatory approval. Within the framework of the collaboration, ConvaTec will leverage its strong global presence and well-established best in class commercial infrastructure to support the commercialization and go-to-market activities for ChloraSolv. RLS will be responsible for continued research and development and ConvaTec will take the lead for go-to-market activities for ChloraSolv.

“For the past six months, ConvaTec has thoroughly evaluated the product ChloraSolv and RLS. We concluded that ChloraSolv, with its unique properties, will be an important addition to ConvaTec’s Wound HygieneTM offering to customers. Gentle yet effective wound debridement is an important component to safe and effective wound healing, and it is critical that more patients have access to this treatment in the future. RLS has an experienced team on board, with impressive knowledge of the advanced wound care business, and has built a very clear and comprehensive roadmap to bring this product to the market. We look forward to establishing a long-term collaboration with RLS”, commented David Shepherd, President & COO, AWC.

 “This collaboration is a breakthrough for RLS and aligned with our vision of being a leading research driven platform company. We are pleased to establish this collaboration with one of the world’s largest wound care companies and that RLS now has access to a comprehensive global distribution channel supported by a committed and competent partner. RLS and ConvaTec share a common view of ChloraSolv’s patient benefits and its contribution to more cost-effective wound care”, says Karin Fischer – CEO of RLS.



ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit


About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: Read more at


Sandrine Letellier, Vice President Global Marketing Advanced Wound Care, ConvaTec Ltd, email:

Cookies are needed for this website to work optimally. They also help us to know a little bit about how you use our website, which improves the browsing experience.  Cookies on this site are used for traffic measurement and optimisation of page content only. By continuing to browse on this website, you indicate your consent to the use of cookies.  You may block the use of cookies by following the "How to block and avoid cookies" instructions

Learn more about our Cookie policy